Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Gottlieb

Showing results (341-350 of 609) with videos related to

Pageof 61
Sort By:
Infection Control and Hospital Epidemiology|February 14, 2024
Implementation of contact precautions for multidrug-resistant organisms in the post-COVID-19 pandemic era: An updated national Emerging Infections Network (EIN) surveyJessica R Howard-Anderson, Lindsey B Gottlieb, Susan E Beekmann, et al.
Journal of Drugs in Dermatology : JDD|August 13, 2015
Tumor Necrosis Factor Inhibitor Primary Failure Predicts Decreased Ustekinumab Efficacy in Psoriasis PatientsEric P Sorensen, Kristina A Fanucci, Ami Saraiya, et al.
American Journal of Clinical Dermatology|August 28, 2019
Treatment of Medicare Patients with Moderate-to-Severe Psoriasis who Cannot Afford Biologics or ApremilastNicola E Natsis, Joseph F Merola, Jeffrey M Weinberg, et al.
The British Journal of Dermatology|October 6, 2007
Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeksR Krishnan, D Cella, C Leonardi, et al.
Dermatology and Therapy|December 6, 2017
The Development of a Patient-Reported Outcome Measure for Assessment of Genital Psoriasis Symptoms: The Genital Psoriasis Symptoms Scale (GPSS)Alice B Gottlieb, Brian Kirby, Caitriona Ryan, et al.
The Journal of Clinical and Aesthetic Dermatology|December 19, 2025
Hidradenitis Suppurativa Patients Experience a Significant Musculoskeletal Symptom Burden: A Quality Improvement Initiative Using the IDEOM MSK-QSarah Romanelli, Gretchen D Ball, Hassan Hamade, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 8, 2018
Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trialsA B Gottlieb, K Gordon, S Hsu, et al.
The Journal of Dermatological Treatment|October 7, 2020
Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trialsAlice B Gottlieb, Jashin J Wu, Christopher E M Griffiths, et al.
The British Journal of Dermatology|November 26, 2013
Diagnosing and treating psoriatic arthritis: an updateW H Boehncke, A Qureshi, J F Merola, et al.
Journal of Drugs in Dermatology : JDD|August 27, 2020
The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2)M Alan Menter, Nehal N Mehta, Mark G Lebwohl, et al.
Pageof 61

Showing results (341-350 of 609) with videos related to

Sort By:
Pageof 61
Infection Control and Hospital Epidemiology|February 14, 2024
Implementation of contact precautions for multidrug-resistant organisms in the post-COVID-19 pandemic era: An updated national Emerging Infections Network (EIN) surveyJessica R Howard-Anderson, Lindsey B Gottlieb, Susan E Beekmann, et al.
Journal of Drugs in Dermatology : JDD|August 13, 2015
Tumor Necrosis Factor Inhibitor Primary Failure Predicts Decreased Ustekinumab Efficacy in Psoriasis PatientsEric P Sorensen, Kristina A Fanucci, Ami Saraiya, et al.
American Journal of Clinical Dermatology|August 28, 2019
Treatment of Medicare Patients with Moderate-to-Severe Psoriasis who Cannot Afford Biologics or ApremilastNicola E Natsis, Joseph F Merola, Jeffrey M Weinberg, et al.
The British Journal of Dermatology|October 6, 2007
Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeksR Krishnan, D Cella, C Leonardi, et al.
Dermatology and Therapy|December 6, 2017
The Development of a Patient-Reported Outcome Measure for Assessment of Genital Psoriasis Symptoms: The Genital Psoriasis Symptoms Scale (GPSS)Alice B Gottlieb, Brian Kirby, Caitriona Ryan, et al.
The Journal of Clinical and Aesthetic Dermatology|December 19, 2025
Hidradenitis Suppurativa Patients Experience a Significant Musculoskeletal Symptom Burden: A Quality Improvement Initiative Using the IDEOM MSK-QSarah Romanelli, Gretchen D Ball, Hassan Hamade, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 8, 2018
Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trialsA B Gottlieb, K Gordon, S Hsu, et al.
The Journal of Dermatological Treatment|October 7, 2020
Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trialsAlice B Gottlieb, Jashin J Wu, Christopher E M Griffiths, et al.
The British Journal of Dermatology|November 26, 2013
Diagnosing and treating psoriatic arthritis: an updateW H Boehncke, A Qureshi, J F Merola, et al.
Journal of Drugs in Dermatology : JDD|August 27, 2020
The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2)M Alan Menter, Nehal N Mehta, Mark G Lebwohl, et al.
Pageof 61